

Tykerb - (EQ 250MG BASE; Tablet)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Lapatinib Ditosylate | Innovator | Novartis |
| Dosage | EQ 250MG BASE; Tablet | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | TYKERB is a kinase inhibitor indicated in combination with: • capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. • letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.